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Resveratrol, a naturally occurring stilbene, induced apoptosis in human breast cancer MCF-7 cells. The mechanism of this effect was
dependent on mitogen-activated protein kinase (MAPK, ERK1/2) activation and was associated with serine phosphorylation and
acetylation of p53. Treatment of MCF-7 cells with resveratrol in the presence of 17b-oestradiol (E2) further enhanced MAPK
activation, but E2 blocked resveratrol-induced apoptosis, as measured by nucleosome ELISA and DNA fragmentation assays. E2
inhibited resveratrol-stimulated phosphorylation of serines 15, 20 and 392 of p53 and acetylation of p53 in a concentration- and time-
dependent manner. These effects of E2 on resveratrol action were blocked by ICI 182,780 (ICI), an inhibitor of the nuclear oestrogen
receptor-a (ER). ICI 182,780 did not block the actions of resveratrol, alone. Electrophoretic mobility studies of p53 binding to DNA
and of p21 expression indicated that E2 inhibited resveratrol-induced, p53-directed transcriptional activity. These results suggest that
E2 inhibits p53-dependent apoptosis in MCF-7 cells by interfering with post-translational modifications of p53 which are essential for
p53-dependent DNA binding and consequent stimulation of apoptotic pathways. These studies provide insight into the complex
pathways by which apoptosis is induced by resveratrol in E2-depleted and -repleted environments.
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Resveratrol is a phytoalexin that occurs naturally in grape skin and
several medicinal plants (Jeanet et al, 1991; Lu and Serrero, 1999).
It has anticancer (Jang et al, 1997) and other biologic properties
(Pace-Asciak et al, 1995). The mechanism of the antitumour effect
of resveratrol is not well understood, but in some tumour cell
models induction of apoptosis is involved (Clement et al, 1998;
Huang et al, 1999; She et al, 2001). We have demonstrated
resveratrol-induced apoptosis in four thyroid cancer cell lines
(Shih et al, 2002) and two prostate cancer cell lines (Lin et al,
2002). Resveratrol has been shown to exert mixed oestrogen
agonist/antagonist activities in mammary cancer cell cultures, but
in the presence of 17b-oestradiol (oestradiol, E2), resveratrol may
function as an antioestrogen (Bhat et al, 2001), antagonising E2
activities. In this study, we have explored the effects of resveratrol
and E2, both separately and together, in breast cancer (MCF-7)
cells, and show that E2 inhibits resveratrol-induced apoptosis in
these cells.
p53 is an oncogene suppressor protein that is present at low
levels in normal cells (Higashimoto et al, 2000). In response to a
variety of stresses, including DNA damage (Higashimoto et al,
2000), levels of cellular p53 protein rise; this increase in p53 results
at least in part from a post-translational mechanism that stabilises
the protein (Ashcroft and Vousden, 1999). p53 can adopt two
forms in vitro, a latent form that binds naked DNA poorly and an
active form that binds to DNA well. Conversion of the latent form
to the active form is thought to occur by an allosteric mechanism
conditioned by phosphorylation and acetylation (Sakaguchi et al,
1998; Liu et al, 1999; Prives and Manley, 2001). Serine
phosphorylation of wild-type p53 at different sites has different
biological consequences (Agarwal et al, 1998). We and others have
shown that resveratrol-induced serine phosphorylation of p53 in
various cancer cells is essential to resveratrol-induced apoptosis
(She et al, 2001; Lin et al, 2002; Shih et al, 2002). Acetylation of p53
occurs in the wake of serine phosphorylation and is essential for
p53-dependent gene expression (Berlev et al, 2001). In this report,
we show that although both E2 and resveratrol stimulate mitogen-
activated protein kinase (MAPK; ERK1/2) activity in an additive
manner in MCF-7 breast cancer cells, E2 inhibits resveratrol-
induced serine phosphorylation and acetylation of p53, as well as
oligonucleotide binding of p53. As a result, resveratrol-induced
p53-dependent p21 gene expression and apoptosis are inhibited by
E2 in these breast cancer cells.
MATERIALS AND METHODS
Cell lines and reagents
The MCF-7 human breast cancer cells were provided by Dr J
Bennett (Albany Medical College, Albany, NY, USA). Cell lines
were maintained for study in DMEM supplemented with 10%
foetal bovine serum (FBS), in a 5% CO2/95% O2 incubator at 371C.
Cells were placed in 0.25% serum-supplemented medium for 2
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sdays prior to treatment. The serum used for these studies was
previously depleted of oestradiol by ion exchange resin, resulting
in a total E2 concentration in undiluted serum of o10
 11 M (Dr Z
Cao, New York State Department of Health, Albany, NY, USA,
personal communication). Oestradiol and resveratrol were ob-
tained from the Sigma Chemical Company (St Louis, MO, USA),
and ICI 182,780 was obtained from Tocris Cookson Inc. (Ellisville,
MO, USA).
Cell fractionation
Fractionation and preparation of nucleoproteins was carried out
according to our previously reported methods (Shih et al, 2001;
Lin et al, 2002). Nuclear extracts were prepared by resuspension of
the crude nuclei in hypotonic buffer with 420mM NaCl, 20%
glycerol at 41C with rocking for 1h, and the supernatants were
collected after subsequent centrifugation at 41C and 13000rpm for
10min.
Immunoblotting
The techniques are standard and have been previously described
(Shih et al, 2001; Lin et al, 2002). Nucleoproteins were separated
on discontinuous SDS–PAGE (9% gels), and then transferred by
electroblotting to Immobilon membranes (Millipore, Bedford, MA,
USA). After blocking with 5% milk in Tris-buffered saline
containing 0.1% Tween, the membranes were incubated overnight
with polyclonal antibodies to phosphorylated ERK1/2, or serine 6-
(ser6-), ser15-, ser20- or ser392-phosphorylated p53 (Cell Signal-
ing, Beverly, MA, USA). A polyclonal antibody to acetylated p53
was from Upstate Biotechnology (Lake Placid, NY, USA). The
secondary antibody was goat anti-rabbit IgG (1:1000, Dako,
Carpenteria, CA, USA). Immunoreactive proteins were detected by
chemiluminescence (Amersham Life Science, Arlington Heights,
IL, USA). All immunoblots were scanned and optical densities of
bands were measured. Immunoblots shown in the figures are
representative of three experiments. Statistical significance of
changes in phosphorylation of ERKs 1 and 2, and of p53, as well as
p53 acetylation, was calculated by one-way analysis of variance on
data from three experiments. Molecular weight markers are
included in Figure 1 for reference; band molecular weights are
similar to those in Figure 1 in Figures 2–5.
Electrophoretic mobility gel shift assay (EMSA)
Nuclear extracts (10mg protein) were incubated in a 25ml total
reaction volume that contained 10mM TRIS, pH 7.5, 50mM NaCl,
1.0mM MgCl2, 0.5mM EDTA, 0.5mM DTT, 4% glycerol and
0.05mgml
 1 poly(dI-dC) (Promega, Madison, WI, USA). A p53-
binding oligonucleotide (Santa Cruz, Santa Cruz, CA, USA),
labelled with [
32P] by T4 polynucleotide kinase (Promega), was
added to the total reaction mixture, which was then incubated for
20min at room temperature. A control nonreactive SP-1
oligonucleotide (Promega) was prepared in the same manner.
Samples were loaded on 4% polyacrylamide gels in low ionic
strength buffer (22.3mM Tris, 22.2 mM borate, 0.5mM EDTA) and
run with cooling at 15Vcm
 1. The gels were then dried, exposed to
X-ray film and autoradiographs were analysed.
RT–polymerase chain reaction (PCR)
Total RNA was isolated as described previously (Shih et al, 2002).
First-strand complementary DNAs were synthesised from 1mg of
total RNA using oligo-deoxythymidine and AMV Reverse Tran-
scriptase (Promega). First-strand cDNA templates were amplified
for p21 and GAPDH by PCR using a hot start (Ampliwax, Perkin
Elmer, Foster City, CA, USA). Primer sequences were as previously
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Figure 1 Resveratrol treatment of MCF-7 cells leads to phosphorylation
(activation) of MAPK, serine phosphorylation of p53 and acetylation of p53
in MCF-7 breast cancer cells. Cells were treated with 1–100mM resveratrol
(RV) for 4h. Nuclear proteins were separated by electrophoresis, and
immunoblots performed with selected antibodies. Mitogen-activated
protein kinase activation, shown as appearance in nuclei of nuclear
phosphorylated ERK1 and ERK2 (pERK1 and 2), and phosphorylation of
serines 15, 20 and 392 of p53, as well as acetylation of p53, were induced
by resveratrol in a concentration-dependent manner (lanes 2–4). Increases
in phosphorylation of ERK1/2 and acetylation and phosphorylation of p53
with 1–100mM RV were each significant at Po0.001 by one-way analysis of
variance in three similar experiments. The graph below shows the changes
in phosphorylation of ERK1/2 and p53, and acetylation of p53, normalized
to a value of 1 in control samples, in three experiments. Means 7 s.e.m. are
shown. Immunoblots of total nuclear ERKs 1 and 2 (second panel from top)
are consistent with activation (phosphorylation) and nuclear accumulation
of these proteins, and a slight increase in total nuclear p53 is consistent with
the resveratrol effect which we have previously described (Lin et al, 2002;
Shih et al, 2002). Actin immunoblots serve as loading controls in this and
subsequent figures. Immunoblots in all figures are representative of three or
more experiments. Molecular weights of the proteins shown are as follows:
pERK1, 44kDa; pERK2, 42kDa; p53, 53kDa; actin, 43kDa. (I.O.D.,
integrated optical density).
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sdescribed (Shih et al, 2002). The PCR cycle was an initial step of
951C for 3min followed by 941C for 1min, 551C for 1min, 721C for
1min, then 25 cycles and a final cycle of 721C for 8min.
Polymerase chain reaction products were subjected to electro-
phoresis in 2% agarose gels containing 0.2mgml
 1 ethidium
bromide. Gels were visualised under UV light and photographed
with Polaroid film (Polaroid Co., Cambridge, MA, USA). Photo-
graphs were scanned under direct light (Bio-Image, Millipore) for
quantitation and illustration. Results of p21 cDNA levels were
normalised to GADPH cDNA levels from the same samples.
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Figure 2 Activation of p53 and apoptosis induced by resveratrol is
inhibited by pifithrin-a in MCF-7 cells. (A) Cells were treated with 10mM
resveratrol (RV) for 4h in the presence or absence of 20mM pifithrin-a
(PFT-a), a specific p53 inhibitor. As shown by immunoblots of nuclear
fractions from a representative experiment above, and the accompanying
graph below, resveratrol caused nuclear accumulation, serine phosphoryla-
tion and acetylation of p53 (Po0.05 comparing lanes 1 and 3 for each
parameter). Treatment with PFT-a resulted in decreased phosphorylation
and acetylation of p53 (Po0.05 for all parameters, comparing lanes 3 and
4). Molecular weight markers in this figure are not shown, but are similar to
those shown in Figure 1. (B) Cells were treated with 10mM resveratrol for
24h in the presence or absence of 20mM PFT-a. Apoptosis, shown by an
increase in nucleosome content determined by ELISA, occurred with
resveratrol treatment (Po0.001, comparing lanes 1 and 3. Pifithrin-a had
no effect alone, but significantly blocked resveratrol-induced apoptosis
(comparing lanes 3 and 4, Po0.005). Means7s.e.m. of six experiments are
shown.
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Figure 3 E2 inhibition of resveratrol-induced activation of MAPK and
p53 is time dependent. MCF-7 cells were treated with E2 (10
 9 M) alone
for 4h or for different time periods (0–4h) with resveratrol (RV, 10mM,
4h), after which nuclear fractions were prepared from each sample. This
series of immunoblots, representative of three experiments, indicates that
minimal activation of ERK1/2 by resveratrol (top panel, lane 3) was
enhanced by 1–2h incubation with E2 (lanes 4 and 5). A longer incubation
with E2 caused a time-dependent reduction in ERK1/2 phosphorylation
(lanes 4–7, Po0.05). Resveratrol induced phosphorylation of serines 15,
20 and 392 of p53 (pSer15-, pSer20- and pSer392-p53), and acetylation of
p53 (lane 3 in each panel). However, these effects of resveratrol on p53
post-translational modification were progressively inhibited by coincubation
with E2 for 1–4h. The reductions in resveratrol-induced serine-15, serine-
20, and serine-392 phosphorylation and acetylation of p53 by E2 were
significant at Po0.003 or less. Molecular weight markers in this figure are
not shown, but are similar to those shown in Figure 1.
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Cells were harvested and washed twice with phosphate-buffered
saline. Nucleosome ELISA assays were carried out according to the
protocol provided by Oncogene Research Products (Cambridge,
MA, USA) (Lin et al, 2002).
Apoptosis/DNA fragmentation
Total genomic DNA was extracted according to the protocol of the
SUICIDE-TRACKt DNA LADDER ISOLATION KIT (Oncogene,
Cambridge, MA, USA). DNA electrophoresis was performed in
1.5% agarose gels containing 0.2mgml
 1 of ethidium bromide.
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Nucleosome ELISA
A
B
Figure 4 E2 inhibits resveratrol-induced p53 phosphorylation and
acetylation, and subsequent apoptosis, in a concentration-dependent
manner. (A) MCF-7 cells were treated with E2 (10
 11–10
 9 M) with or
without resveratrol (RV, 10mM) for 4h. Immunoblots of nuclear fractions
from this representative experiment show that resveratrol-induced MAPK
activation (pERK1/2, top panel, lane 3) was enhanced by 10
 11–10
 9 M E2
(lanes 3–6; Po0.005). However, resveratrol-induced ser15, ser20 and
ser392 phosphorylation of p53, as well as acetylation of p53, was inhibited
by E2 in a dose-dependent manner (Po0.001, lanes 3–6 for all these
parameters), with the most marked inhibition occurring at 10
 9 M E2 (lane
6). Molecular weight markers in this figure are not shown, but are similar to
those shown in Figure 1. (B) This graph shows the extent of apoptosis,
measured by nucleosome ELISA, in MCF-7 cells treated with E2 (10
 11–
10
 9 M) with or without resveratrol (RV, 10mM) for 24h. Resveratrol alone
caused apoptosis (lane 3, Po0.001). E2 alone did not induce apoptosis, but
the hormone inhibited nucleosome formation induced by resveratrol in a
dose-dependent manner (Po0.001). Means7s.e.m. of five experiments
are shown.
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Figure 5 ICI 182,780 (ICI) inhibits the effects of E2 on resveratrol-
induced activation of MAPK and p53. MCF-7 cells were pretreated with
3n M ICI or diluent for 30min, after which they were treated with 10
 9 M E2
and/or 10mM resveratrol for 4h along with continued 3nM ICI or diluent as
in the pretreatment period. Results shown are representative of three
experiments. Immunoblots of nuclear fractions show that ICI minimally
inhibited E2-induced MAPK activation (comparing lanes 3 and 4), but did
not inhibit resveratrol-induced MAPK activation (lanes 5 and 6). ICI
182,780 did enhance resveratrol-induced ser15-p53 phosphorylation,
although this effect was not statistically significant. The additive effect on
MAPK activation of E2 and resveratrol was reduced by ICI (Po0.05, lane 7
vs lane 8), and the inhibitory effect of E2 on resveratrol-induced serine
phosphorylation and acetylation of p53 was partially reversed by ICI
treatment (Po0.02 for each parameter, comparing lanes 7 and 8).
Molecular weight markers in this figure are not shown, but are similar to
those shown in Figure 1.
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Polaroid film (Polaroid Co., Cambridge, MA, USA). Photographs
were scanned under direct light (BioImage, Millipore) for
quantitation and illustration.
RESULTS
Effects of resveratrol and a p53 inhibitor on MAPK
activation, p53 phosphorylation and apoptosis in MCF-7
cells
Initial studies focused on the effects of resveratrol on phosphor-
ylation, or activation, of MAPK (pERK1/2) and p53, and
accumulation of these phosphorylated proteins in nuclear fractions
of MCF-7 cells (Figure 1). Treatment of these cells with 1–100mM
resveratrol for 4h induced MAPK phosphorylation and serine
phosphorylation of p53 at residues 15, 20 and 392. In addition,
acetylation of p53 was induced by resveratrol treatment (Figure 1).
Phosphorylation of ERK1 and ERK2, and of p53, resulted in
translocation of these proteins to cell nuclei. The combined results
from three experiments, normalised to a value of 1 in control
samples, are shown in the graph of Figure 1.
In order to determine if resveratrol-induced apoptosis was p53
dependent, a specific p53 inhibitor, pifithrin-a (PFT-a) (Komarov
et al, 1998), was added to cells in the presence or absence of
resveratrol. Resveratrol-induced phosphorylation of serines 15, 20
and 392, and acetylation of p53, were inhibited by PFT-a
(Figure 2A). In Figure 2B, the combined results of three
nucleosome ELISA studies show a five-fold increase in nucleosome
content in cells treated with resveratrol, and a reduction in the
resveratrol effect with PFT-a. Increased nucleosome content is
directly related to apoptosis (Lin et al, 2002; Shih et al, 2002).
These findings indicate that resveratrol-induced apoptosis in MCF-
7 cells is p53-dependent.
Effect of oestradiol on resveratrol-induced MAPK
activation, serine phosphorylation of p53 and apoptosis
In a 4h study with MCF-7 cells, E2 (10
 9 M) caused phosphoryla-
tion (activation) and nuclear translocation of MAPK, shown as
pERK1 and pERK2 in Figure 3, lane 2. Furthermore, in cells treated
with 10mM resveratrol for 4h, 1–4h of E2 exposure enhanced the
activation and nuclear translocation of MAPK caused by
resveratrol (lanes 4–7 compared with lane 3). In contrast to this
enhancement by E2 of resveratrol-induced MAPK activation, the
hormone inhibited resveratrol-induced serine phosphorylation of
p53 in a time-dependent manner. Phosphorylation of serines 15, 20
and 392 by resveratrol, as well as acetylation of p53, were all
progressively reduced in resveratrol-treated MCF-7 cells by the
addition of E2 to resveratrol for 1–4h.
In E2 concentration–response studies, there was hormone
concentration-dependent enhancement of resveratrol-stimulated
MAPK activation with 10
 11–10
 9 M E2 (Figure 4A, lanes 4–6) but
reduction in resveratrol-induced phosphorylation of p53 serines
15, 20 and 392, and reduction in acetylation of p53 after treatment
with both agents for 4h (lanes 4–6). These latter effects were also
E2 concentration-dependent. The effect of 10
 11–10
 9 M E2 on
resveratrol-induced apoptosis in MCF-7 cells, indicated by
nucleosome ELISA, is shown in Figure 4B. Dose-responsive
inhibition by E2 of apoptosis in these resveratrol-treated cells
correlates directly with the reduction in post-translational
modification of p53 seen in Figure 4A, above.
Effect of the oestrogen receptor-a (ER) inhibitor, ICI
182,780, on actions of resveratrol and oestradiol
E2 has been shown to block chemotherapy- or radiation-induced
apoptosis through a plasma membrane receptor that appears to be
the nuclear ER located in the cell membrane (Razandi et al, 2000).
Therefore, we tested the E2 effect on resveratrol action in the
presence of ICI 182,780 (ICI), an inhibitor of ER (Papaconstanti-
nou et al, 2002). ICI 182,780 partially suppressed E2-induced
ERK1/2 phosphorylation, or activation (Figure 5, comparing lanes
3 and 4). ICI 182,780 did not inhibit resveratrol-induced post-
translational modifications of p53 (lane 5 vs lane 6). ICI 182,780
did enhance the effect of resveratrol on serine-15 phosphorylation
of p53 (lane 6), although this effect was not statistically significant.
E2 blocked serine phosphorylation and acetylation of p53 caused
by resveratrol (lane 7), but in the presence of E2 and ICI, the
inhibitory effect of the hormone on phosphorylation and
acetylation of p53 was not seen (lane 8). In summary, signal
transduction by resveratrol was enhanced by ICI, and the action on
MAPK activation by E2 alone was inhibited by ICI. The inhibitory
effect of E2 on resveratrol-induced phosphorylation and acetyla-
tion of p53 appears to be ER-mediated, in that this hormone effect
was reversed by the ER inhibitor.
Oestradiol inhibits resveratrol-induced p53 binding to
DNA and p53-dependent gene expression
We studied the interaction of p53 with a p53-binding radiolabelled
oligonucleotide added to nuclear extracts from resveratrol-treated
cells, in the presence or absence of E2. Results shown in Figure 6
indicate that (1) resveratrol caused binding of p53 to the labelled
oligonucleotide, and (2) E2 inhibited interaction of p53 and the
oligonucleotide. Therefore, E2 not only inhibits resveratrol-
induced post-translational modification of p53 as shown above
in Figures 3–5 but also inhibits DNA binding by p53.
Resveratrol is known to induce p53-dependent p21 expression in
human thyroid cancer cells (Shih et al, 2002), an effect that is
associated with apoptosis in these cells. Induction by resveratrol of
p21 expression in MCF-7 cells has been previously shown to lead to
apoptosis (Pozo-Guisado et al, 2002). In our studies of transcrip-
tion by RT–PCR in MCF-7 cells, we found that resveratrol caused
transcription of p21, and that E2 inhibited this action of the
123456
-p53-binding
site
RV (10 µM)
E2 (10
−9 M)
−
−− −− ++
+−+++
Excess SP-1
Excess p53
Figure 6 E2 inhibits resveratrol-induced p53 binding to a relevant
oligonucleotide in an EMSA. The assay was carried out with nuclear
fractions prepared after 4h treatment of cells with 10mM resveratrol,
10
 9 M E2, or both agents. p53 binding to the radiolabelled oligonucleotide
was seen (lane 2). E2 inhibited p53 binding (lane 4 compared with lane 2).
Excess unlabelled oligonucleotide (p53-oligo) decreased p53 binding to the
labelled form (lane 6), whereas there was no change in p53 binding with an
excess of unlabelled nonspecific SP-1 oligonucleotide (lane 5). This figure is
representative of three similar experiments.
Oestrogen, resveratrol and p53 in breast cancer
S Zhang et al
182
British Journal of Cancer (2004) 91(1), 178–185 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sstilbene (Figure 7A). The biological end point of this effect of E2
was inhibition of resveratrol-induced apoptosis, as indicated by
loss of DNA fragmentation (Figure 7B) and nucleosome ELISA
(Figure 4B).
Oestradiol, 10
 9 M, had no effect alone on p21 expression in our
experiments. Cariou et al (2000) have described a transient
increase in p21 content after 4h treatment with 10
 8 M E2 in MCF-7
cells, whereas in our studies, a lower concentration of hormone
was used for 24h. Others have reported that E2 can enhance
abundance of p21 mRNA in D351 breast cancer cells (Levenson
et al, 2003). The basis for these disparate effects of E2 is not clear,
although differences in cell lines, in hormone concentration or in
exposure time of cells to E2 (Levenson et al, 2003) may have
contributed to the different results. The D351 cells used by
Levenson and co-workers were MDA-MB-231 cells transfected with
cDNA for wt ER, but the p53 in these cells is said to be
nonfunctional (Toillon et al, 2002).
DISCUSSION
Resveratrol, a phyto-oestrogen based on the fact that it binds to
and activates ER, has similar affinity for ERa and ERb, but with
7000-fold lower affinity than E2 (Bowers et al, 2000). As has been
shown for other selective ER modulators such as tamoxifen,
resveratrol has been considered to have potential as an anti-breast
cancer adjunct (Bhat et al, 2001). The stilbene has been shown to
inhibit carcinogen-induced preneoplastic lesions and mammary
tumours in rodent models (Bhat et al, 2001). In the present studies,
treatment of MCF-7 breast cancer cells with 1–100mM resveratrol
induced MAPK activation, serine phosphorylation and acetylation
of p53 and p53-dependent apoptosis. In addition to these findings
in breast cancer cells, we have previously shown that human
thyroid and prostate cancer cells are susceptible to resveratrol-
induced, p53-dependent apoptosis (Lin et al, 2002; Shih et al,
2002).
We have examined the possibility that the actions of resveratrol
on MCF-7 cells might be modified by E2. Acting at the cell surface,
oestradiol has been shown by several investigators to rapidly
activate MAPK (Migliaccio et al, 1996; Razandi et al, 2003; Wade
and Dorsa, 2003). We have confirmed this action of E2 in MCF-7
cells in this report (Figures 3–5). Mitogen-activated protein kinase
activation induced by oestrogen in breast cancer cells has been
linked to cell proliferation but there have been no reports to
indicate that MAPK activation in breast cancer cells is involved in
apoptosis (Santen et al, 2002). In our studies, treatment of MCF-7
cells with 10mM resveratrol in the presence of 10
 9 M E2 produced
additive MAPK activation by E2 and resveratrol. However, E2
inhibited resveratrol-induced phosphorylation of serines 6, 15 and
392 in p53, as well as acetylation of p53, despite the enhancement
by E2 of MAPK activity.
A downstream effect of this action of oestrogen on MAPK
activation may be phosphorylation of Ser-118 of ERa and
enhanced transcriptional activity of the receptor (Kato et al,
1995). We did not observe apoptosis as a downstream consequence
of MAPK activation by E2 alone, compared with the actions of
resveratrol. Thus, the confluence at MAPK of signals generated by
resveratrol and E2 results, downstream of MAPK, in a divergence
of effects on nuclear transcription by p53 and by E2. This is
consistent with the existence of discrete intracellular pools of
MAPK (ERK1/2) separately regulated by resveratrol and E2.
The antiapoptotic effect of E2 in the presence of resveratrol
involves rapid stimulation of signalling cascades, including the
ERK1/2 pathway. In our studies, the ER inhibitor ICI 182,780
suppressed both E2-induced MAPK activation and the inhibitory
effect of E2 on resveratrol-induced serine phosphorylation of p53.
Although resveratrol has been shown by others to have oestrogen-
like activity in a transcriptional assay in cells expressing
predominantly ERa (Bhat et al, 2001), we found that ICI 182,780,
in a relatively low concentration of 3nM, did not diminish
resveratrol-induced activation of MAPK and serine phosphoryla-
tion of p53, and in fact appeared to enhance these effects of the
stilbene. The concentration we used was similar to the inhibitory
10nM concentration used in MCF-7 cells by Cariou et al (2000).
Others have also reported that activities of resveratrol are not
affected by ICI 182,780 (Cho et al, 2002). Since E2 action was
inhibited by ICI 182,780 in our studies, while resveratrol activity
was minimally affected by ICI 182,780, the inhibitory effect of E2
on resveratrol-induced serine phosphorylation of p53 was inter-
preted to be ER mediated. Studies by others have shown that ICI
182,780 may enhance the effects of doxorubicin, paclitaxol and
tumour necrosis factor-a on the production of apoptosis in MCF-7
cells (Burow et al, 2001).
Oestradiol alone had no effect on the binding of p53 to a
relevant oligonucleotide. However, E2 did inhibit resveratrol-
induced binding of p53 to the oligonucleotide (Figure 6). This
finding is consistent with E2 inhibition of post-translational
modifications of p53 that are essential for p53-dependent gene
transcription. These results have implications for the possible use
of resveratrol therapeutically in cancer treatment, as they suggest
that resveratrol may be most effective in an oestrogen-depleted
environment.
The transcriptional activity of p53 is subject to modulation by
other hormones as well. For example, glucocorticoids prevent p53-
induced apoptosis through interaction of the glucocorticoid
receptor (GR) with p53 and the E3 ubiquitin ligase, Hdm2
(Sengupta and Wasylyk, 2001) in cytosol. Another example of a
modulator is the mdm2 gene that is positively regulated by p53, yet
the mdm2 protein binds p53, forming a feedback loop that
controls mdm2 activity (Qi et al, 1999).
MCF-7 cells MCF-7 cells
123 4
-p21
-GAPDH
3
2
1
0
E2
E2
−
−
+
+−+
−+
−
−−
−+ +
++
RV
RV
F
o
l
d
 
i
n
c
r
e
a
s
e
 
o
f
 
I
.
O
.
D
.
12 34
AB
Figure 7 E2 inhibits p53-inducible p21 expression and apoptosis caused
by resveratrol. (A) MCF-7 cells were treated with 10mM resveratrol in the
presence or absence of 10
 9 M E2 for 24h. Based on measurement of p21
and GAPDH cDNA band densities (upper and lower images, respectively),
and correction of p21 densities for the levels of GAPDH, a 2.5-fold increase
in p21 cDNA abundance was seen with resveratrol treatment (lane 3
compared with lane 1). This increase in p21 expression was significant
(Po0.025) by analysis of variance. E2,1 0
 9 M, blocked p21 transcription
induced by resveratrol (lane 4 compared with lane 3, Po0.05), but had no
effect in the absence of resveratrol. (B) MCF-7 cells were treated with
10mM resveratrol in the presence or absence of 10
 9 M E2 for 24h.
Resveratrol caused DNA fragmentation, indicating apoptosis as shown in
this representative figure (lane 3). This effect of resveratrol was inhibited by
E2 (lane 4).
Oestrogen, resveratrol and p53 in breast cancer
S Zhang et al
183
British Journal of Cancer (2004) 91(1), 178–185 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sSince the effect of resveratrol that we have demonstrated in
MCF-7 cells centres on the modification and action of the tumour
suppressor p53, it is conceivable that cancer cells harbouring
mutant p53 might not respond in the same manner. However,
studies by Hsieh et al (1999) have documented resveratrol-induced
reduction in growth of MDA-MB-435 cells, which contain a mutant
p53. In our studies of the actions of resveratrol on DU145 prostate
cancer cells, which also contain mutant p53 (Zhang et al, 2003),
resveratrol did induce apoptosis. Future studies are to be directed
towards the identification of critical sites on p53 for resveratrol
action.
The present studies indicate that ambient E2 may antagonise
actions of resveratrol in selected treatment paradigms. Our results
suggest the complexity of actions of resveratrol in both in vivo and
in vitro settings. Were resveratrol to be tested in intact animals, it
would be important to control for levels of oestrogen, and useful to
examine actions of the stilbene in the presence of an E2 antagonist.
ACKNOWLEDGEMENTS
This work has been supported by grants from the Research
Service, United States Department of Veterans Affairs, and from
the Charitable Leadership, Candace King Weir and Beltrone
Foundations.
REFERENCES
Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR (1998) The
p53 network. J Biol Chem 273: 1–4
Ashcroft M, Vousden KH (1999) Regulation of p53 stability. Oncogene 18:
7637–7643
Berlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD,
Berger SL (2001) Acetylation of p53 activates transcription
through recruitment of coactivators/histone acetytransferases. Mol Cell
8: 1243–1254
Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM (2001)
Estrogenic and antiestrogenic properties of resveratrol in mammary
tumor models. Cancer Res 61: 7456–7463
Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM (2000) Resveratrol
acts as a mixed agonist/antagonist for estrogen receptors a and b.
Endocrinology 141: 3657–3667
Burow ME, Weldon CB, Tang Y, McLachlan JA, Beckman BS (2001)
Oestrogen-mediated suppression of tumour necrosis factor alpha-
induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens.
J Steroid Biochem Mol Biol 78: 409–418
Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland
JM (2000) Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates
antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc
Natl Acad Sci USA 97: 9042–9046
Cho DI, Koo NY, Chung WJ, Kim TS, Ryu SY, Im SY, Kim KM (2002)
Effects of resveratrol-related hydroxystilbenes on the nitric oxide
production in macrophage cells: structural requirements and mechanism
of action. Life Sci 71: 2071–2082
Clement M-V, Hirpara JL, Chawdhury S-H, Pervaiz S (1998) Chemopre-
ventive agent resveratrol, a natural product derived from grapes, triggers
CD95 signaling-dependent apoptosis in human tumor cells. Blood 92:
996–1002
Higashimoto Y, Saito S, Tong XH, Hong A, Sakaguchi K, Appella E,
Anderson CW (2000) Human p53 is phosphorylated on serines 6
and 9 in response to DNA damage-inducing agents. J Biol Chem 275:
23199–23203
Hsieh TC, Burfeind P, Laud K, Backer JM, Traganos F, Darzynkiewicz Z,
Wu JM (1999) Cell cycle effects and control of gene expression by
resveratrol in human breast cancer cell lines with different metastatic
potentials. Int J Oncol 15: 245–252
Huang C, Ma WY, Goranson A, Dong Z (1999) Resveratrol suppresses cell
transformation and induces apoptosis through a p53-dependent path-
way. Carcinogenesis 20: 237–242
Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH,
Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997)
Cancer chemopreventive activity of resveratrol, a natural product
derived from grapes. Science 275: 218–220
Jeanet P, Bessis R, Gautheron B (1991) The production of resveratrol
(3,5,40-trihydroxystilbene) by grape berries in different stages. Am J Enol
Viticul 42: 41–46
Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Susaki H,
Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P
(1995) Activation of the estrogen receptor through phosphorylation by
mitogen-activated protein kinase. Science 270: 491–1494
Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS,
Chernov MV, Gudkov AV (1998) A chemical inhibitor of p53 that
protects mice from the side effects of cancer therapy. Science 285:
1733–1737
Levenson AS, Gehm BD, Pearce ST, Horiguchi J, Simons LA, Ward III JE,
Jameson JL, Jordan VC (2003) Resveratrol acts as an estrogen receptor
(ER) agonist in breast cancer cells stably transfected with ER alpha. Int J
Cancer 104: 587–596
Lin H-Y, Shih A, Davis FB, Tang H-Y, Martino LJ, Bennett JA, Davis PJ
(2002) Resveratrol-induced serine phosphorylation of p53 causes
apoptosis in a mutant p53 prostate cancer cell line. J Urol 168: 748–755
Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis
TD, Berger SL (1999) p53 sites acetylated in vitro by PCAF and p300
are acetylated in vivo in response to DNA damage. Mol Cell Biol 19:
1202–1209
Lu R, Serrero G (1999) Resveratrol, a natural product derived from grape,
exhibits antiestrogenic activity and inhibits the growth of human breast
cancer cells. J Cell Physiol 179: 297–304
Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E
(1996) Tyrosine kinase/p21ras/MAP-kinase pathway activation by
estradiol-receptor complex in MCF-7 cells. EMBO J 15: 1292–1300
Pace-Asciak C, Hahn R, Diamandis EP, Soleas G, Goldberg DM (1995) The
red wine phenolics trans-resveratrol and quercetin block human platelet
aggregation and eicosanoid synthesis: Implications for protection against
coronary disease. Clin Chim Acta 235: 207–219
Papaconstantinou AD, Umbreit TH, Goering PL, Brown KM (2002) Effects
of 17 alpha-methyltestosterone on uterine morphology and heat shock
protein expression are mediated through estrogen and androgen
receptors. J Steroid Biochem Mol Biol 82: 305–314
Pozo-Guisado E, Alvarez-Barrientos A, Mulero-Navarro S, Santiago-Josefat
B, Fernandez-Salguero PM (2002) The antiproliferative activity of
resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231
human breast cancer cells: cell-specific alteration of the cell cycle.
Biochem Pharmacol 64: 1375–1386
Prives C, Manley JL (2001) Why is p53 acetylated? Cell 107: 815–818
Qi JS, Yuan Y, Desai-Yajnik V, Samuels HH (1999) Regulation of the mdm2
oncogene by thyroid hormone receptor. Mol Cell Biol 19: 864–872
Razandi M, Alton G, Pedram A, Ghonshani S, Webb P, Levin ER (2003)
Identification of a structural determinant necessary for the localization
and function of estrogen receptor a at the plasma membrane. Mol Cell
Biol 23: 1633–1646
Razandi M, Pedram A, Levin ER (2000) Plasma membrane estrogen
receptors signal to antiapoptosis in breast cancer. Mol Endocrinol 14:
1434–1447
Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson
CW, Appella E (1998) DNA damage activates p53 through a phosphor-
ylation–acetylation cascade. Genes Dev 12: 2831–2841
Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W
(2002) The role of mitogen-activated protein (MAP) kinase in breast
cancer. J Steroid Biochem Mol Biol 80: 239–256
Sengupta S, Wasylyk B (2001) Ligand-dependent interaction of the
glucocorticoid receptor with p53 enhances their degradation by Hdm2.
Genes Dev 15: 2367–2380
She QB, Bode AM, Ma WY, Chen NY, Dong Z (2001) Resveratrol-induced
activation of p53 and apoptosis is mediated by extracellular-signal-
regulated protein kinases and p38 kinase. Cancer Res 61: 1604–1610
Oestrogen, resveratrol and p53 in breast cancer
S Zhang et al
184
British Journal of Cancer (2004) 91(1), 178–185 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sShih A, Davis FB, Lin H-Y, Davis PJ (2002) Resveratrol induces apoptosis in
thyroid cancer cell lines via a mitogen-activated protein kinase- and p53-
dependent mechanism. J Clin Endo Metab 87: 1223–1232
Shih A, Lin HY, Davis FB, Davis PJ (2001) Thyroid hormone promotes
serine phosphorylation of p53 by mitogen-activated protein kinase.
Biochemistry 40: 2870–2878
Toillon RA, Chopin V, Jouy N, Fauquette W, Boilly B, Le Bourbis X (2002)
Normal breast epithelial cells induce p53-dependent apoptosis and p53-
independent cell cycle arrest of breast cancer cells. Breast Cancer Res
Treat 71: 269–280
Wade CB, Dorsa DM (2003) Estrogen activation of cyclic adenosine 50-
monophosphate response element-mediated transcription requires the
extracellularly regulated kinase/mitogen-activated protein kinase path-
way. Endocrinology 144: 832–838
Zhang Z, Li M, Wang H, Agrawal S, Zhang R (2003) Antisense therapy
targeting MDM2 oncogene in prostate cancer: effects on proliferation,
apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad
Sci USA 100: 11636–11641
Oestrogen, resveratrol and p53 in breast cancer
S Zhang et al
185
British Journal of Cancer (2004) 91(1), 178–185 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s